Clinical Trial Update: Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects [Phase 1]

View source ↗

Summary

Amgen's Phase 1 study of AMG 333 in healthy subjects and migraine patients has been terminated. The trial evaluated safety, tolerability, pharmacokinetics, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• AMG 333

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 1 | Status: TERMINATED